Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) have announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX’s Probody® therapeutic platform and Regeneron’s Veloci-Bi® bispecific antibody development platform.
Latham & Watkins LLP represented CytomX in the transaction with a corporate deal team led by Bay Area partners Judith Hasko and Mark Roeder, with Los Angeles associate Mike Sweeney. Advice was also provided on tax matters by Bay Area partner Kirt Switzer, with associate Alex Farris.
